| Biomarker ID | 756 |
| PMID | 21917134 |
| Year | 2011 |
| Biomarker | NUF2 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated with high Gleason Score |
| Odds Ratio/Hazard Ratio/Relative Risk | [GS (3+4): HR =25.04 (95% CI: 3.24, 193.72)] ; [GS (4+3): HR = 31.21 (95% CI: (3.66-266.07))] ; [GS (8-10): HR = 33.31 (95% CI: 4.40- 251.92)] |
| Effect on Pathways | Pathways Include:-M phase pathway,DNA replication,Cell cycle |
| Experiment | Gleason Score (≤6, (3+4), (4+3), 8-10) |
| Type of Biomarker | Prognostic |
| Cohort | Specimens from 72 clinically localized PCa cases with follow-up data (29 without recurrence and 43 with recurrence) and 17 clinically localized PCa without follow-up data were collected and frozen at the time of radical prostatectomy |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | For Hazrard Ratio: (p = 0.002) |
| Method Used | real-time PCR |
| Clinical | No |
| Remarks | Multivariate Analysis |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NUF2 |